Beyond surgery, tumor irradiation, and chemotherapy, the management of breast cancer emphasizes the long-term suppression of the action of endogenous estrogen with tamoxifen, or inhibition of estrogen synthesis with aromatase inhibition. This evidence concerns the gene CYP19A1 and breast cancer.